{
  "docId": "019de073-dc46-770c-87a2-2b21d91043e5",
  "docSlug": "4f9fcbb83e828aea5419518c9cca9ae9",
  "documentTitle": "Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides",
  "authorId": "tonix-pharmaceuticals",
  "authorName": "Tonix Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 29,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "other",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide outlines a clinical trial protocol for TNX-102 SL in Long COVID patients.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-dc46-770c-87a2-2b21d91043e5/11",
  "deckHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5",
  "deckJsonHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5.json",
  "deckAnchorHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "diagram",
      "text": "TNX-102 SL once-daily at bedtime (5.6 mg) vs Placebo once-daily at bedtime over 14 weeks.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70d10499-91e0-4ce7-b8b7-d232fa1e0095",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "General study characteristics: Randomized, double-blind, placebo-controlled study in fibromyalgia-type Long COVID; ~30 sites, ~470 patients; one unblinded interim analysis at 50%.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01033c0b-d311-457c-b0f5-7fa873005815",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.04,
        "y": 0.38
      },
      "kind": "list",
      "text": "Primary Endpoint: Daily self-reported worst pain intensity change from baseline at Week 14 (TNX-102 SL vs. placebo); Weekly averages; MMRM with MI analysis.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5903b0e-46b2-4082-909b-46018277c529",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.45,
        "y": 0.62
      },
      "kind": "source-note",
      "text": "Two week run in at 2.8 mg dose at bedtime, followed by 12 weeks at 5.6 mg dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19383ddf-7b59-45d3-b41a-19dd68352987",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Phase 2 PREVAIL Study Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49000e0f-97f3-4db1-ade6-9888b51044c7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 7,
      "beatId": "7e5647ed-6856-422f-b350-52485c939d0b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The presentation outlines the company's product candidates and their potential applications",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e532f435-d20e-4323-8595-44dab22c3ce1",
      "evidence": "The presentation uses a golden circle structure to communicate the company's mission and vision",
      "position": 0,
      "objective": "Why Tonix Pharmaceuticals?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}